AU2003270846B2 - Pyrazolopyridines as cyclin dependent kinase inhibitors - Google Patents

Pyrazolopyridines as cyclin dependent kinase inhibitors Download PDF

Info

Publication number
AU2003270846B2
AU2003270846B2 AU2003270846A AU2003270846A AU2003270846B2 AU 2003270846 B2 AU2003270846 B2 AU 2003270846B2 AU 2003270846 A AU2003270846 A AU 2003270846A AU 2003270846 A AU2003270846 A AU 2003270846A AU 2003270846 B2 AU2003270846 B2 AU 2003270846B2
Authority
AU
Australia
Prior art keywords
aryl
alkyl
group
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003270846A
Other languages
English (en)
Other versions
AU2003270846A1 (en
Inventor
Ronald J. Doll
Michael P. Dwyer
Viyyoor M. Girijavallabhan
Timothy J. Guzi
Kartik M. Keertikar
Kamil Paruch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp & Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2003270846A1 publication Critical patent/AU2003270846A1/en
Application granted granted Critical
Publication of AU2003270846B2 publication Critical patent/AU2003270846B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003270846A 2002-09-19 2003-09-17 Pyrazolopyridines as cyclin dependent kinase inhibitors Ceased AU2003270846B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41213802P 2002-09-19 2002-09-19
US60/412,138 2002-09-19
PCT/US2003/029841 WO2004026872A1 (en) 2002-09-19 2003-09-17 Pyrazolopyridines as cyclin dependent kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2003270846A1 AU2003270846A1 (en) 2004-04-08
AU2003270846B2 true AU2003270846B2 (en) 2006-11-23

Family

ID=32030811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270846A Ceased AU2003270846B2 (en) 2002-09-19 2003-09-17 Pyrazolopyridines as cyclin dependent kinase inhibitors

Country Status (18)

Country Link
US (1) US7151104B2 (cg-RX-API-DMAC10.html)
EP (1) EP1539750B1 (cg-RX-API-DMAC10.html)
JP (1) JP4845380B2 (cg-RX-API-DMAC10.html)
KR (1) KR20050072090A (cg-RX-API-DMAC10.html)
CN (1) CN100475812C (cg-RX-API-DMAC10.html)
AR (1) AR041292A1 (cg-RX-API-DMAC10.html)
AT (1) ATE382048T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003270846B2 (cg-RX-API-DMAC10.html)
CA (1) CA2499593C (cg-RX-API-DMAC10.html)
DE (1) DE60318321T2 (cg-RX-API-DMAC10.html)
ES (1) ES2297203T3 (cg-RX-API-DMAC10.html)
IL (1) IL167432A (cg-RX-API-DMAC10.html)
MX (1) MXPA05003059A (cg-RX-API-DMAC10.html)
MY (1) MY136840A (cg-RX-API-DMAC10.html)
NZ (1) NZ538595A (cg-RX-API-DMAC10.html)
TW (1) TWI283243B (cg-RX-API-DMAC10.html)
WO (1) WO2004026872A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502271B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
CA2603457A1 (en) * 2005-04-07 2006-10-19 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
CA2621983A1 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
CA2670636A1 (en) * 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN107427521B (zh) * 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
US10968215B2 (en) * 2016-09-07 2021-04-06 Shanghai Haihe Pharmaceutical Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035917A1 (fr) * 1999-11-19 2001-05-25 L'oreal COMPOSITIONS DE TEINTURE DES FIBRES KERATINIQUES CONTENANT DES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
EP1043998B1 (en) 1997-12-13 2007-03-07 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
DE60141889D1 (de) * 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
JP2004516297A (ja) * 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） サイクリン依存性キナーゼ（ｃｄｋ）及びグリコーゲンシンターゼキナーゼ−３（ｇｓｋ−３）の阻害剤
CZ20032398A3 (cs) * 2001-03-08 2004-02-18 Astrazeneca Ab Nové použití derivátů 6-karboxamidoimidazo [1,2-a] pyridinu
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035917A1 (fr) * 1999-11-19 2001-05-25 L'oreal COMPOSITIONS DE TEINTURE DES FIBRES KERATINIQUES CONTENANT DES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES

Also Published As

Publication number Publication date
WO2004026872A1 (en) 2004-04-01
ES2297203T3 (es) 2008-05-01
CA2499593A1 (en) 2004-04-01
ZA200502271B (en) 2005-09-19
NZ538595A (en) 2006-04-28
DE60318321T2 (de) 2008-12-11
MXPA05003059A (es) 2005-05-27
AR041292A1 (es) 2005-05-11
EP1539750B1 (en) 2007-12-26
TWI283243B (en) 2007-07-01
JP2006503060A (ja) 2006-01-26
CA2499593C (en) 2011-08-16
ATE382048T1 (de) 2008-01-15
US7151104B2 (en) 2006-12-19
JP4845380B2 (ja) 2011-12-28
EP1539750A1 (en) 2005-06-15
TW200409775A (en) 2004-06-16
CN1681816A (zh) 2005-10-12
MY136840A (en) 2008-11-28
IL167432A (en) 2010-05-17
CN100475812C (zh) 2009-04-08
KR20050072090A (ko) 2005-07-08
DE60318321D1 (en) 2008-02-07
HK1071758A1 (en) 2005-07-29
US20040097516A1 (en) 2004-05-20
AU2003270846A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2003275031B2 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
AU2003295332B2 (en) Imidazopyridines as cyclin dependent kinase inhibitors
AU2003272476B2 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
CA2557184C (en) Pyrazolotriazines as kinase inhibitors
AU2003265901B2 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1534712A2 (en) Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors
CA2499593C (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2007200401A1 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
HK1071758B (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
HK1072056B (en) Imidazopyrazines as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ MERCK SHARP & DOHME CORP. .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired